沙眼衣原体与淋病奈瑟菌实验室分子诊断性能综述
本文系统检索并叙述性综述了145项研究,评估FDA清除的核酸扩增检测(NAAT)在沙眼衣原体(CT)和淋病奈瑟菌(NG)诊断中的性能。多数检测对临床医生采集的生殖器外标本和自采阴道拭子敏感性>90%、特异性>98%,但尚无NAAT获批用于患者自采生殖器外标本。未来需扩展自采生殖器外标本的批准并开发活力检测以区分活动性感染与残留核酸。
要点
- NAAT仍是CT/NG实验室诊断金标准,多数检测对医生采集生殖器外标本和自采阴道拭子敏感性>90%、特异性>98%。
- FDA首次批准非临床环境自采试剂盒是STI诊疗可及性的重大里程碑,但尚无NAAT获批用于患者自采生殖器外标本。
- 尚无FDA清除的检测可区分LGV,但多种实验室自建检测显示前景。
核心结论
- CT/NG分子诊断在标本类型、技术和流程上已有改进,但患者自采生殖器外标本的FDA批准和活力检测仍是未来方向。
研究设计与样本
- 系统文献检索与叙述性综述,评估145项研究,聚焦FDA清除的NAAT、自采标本、汇集策略、转阴时间、确认/重复检测和LGV诊断六个领域。
主要发现
- 多数检测对临床医生采集的生殖器外标本和自采阴道拭子敏感性>90%、特异性>98%。
- FDA首次批准非临床环境自采试剂盒,但尚无NAAT获批用于患者自采生殖器外标本。
- 新版检测加入CT和NG双靶标以提高阳性预测值并减少诊断逃逸。
- 尚无FDA清除的检测可区分LGV,但多种实验室自建检测显示前景。
关键数值与推荐
- NAAT因高敏感性和特异性仍为CT/NG实验室诊断金标准。
- 多数FDA清除的NAAT对医生采集生殖器外标本和自采阴道拭子敏感性>90%、特异性>98%。
- 尚无NAAT获批用于患者自采生殖器外标本。
- 尚无FDA清除的检测可区分LGV。
临床怎么用
- 临床可依据NAAT高敏感性>90%和高特异性>98%解读医生采集生殖器外标本及自采阴道拭子的检测结果。
- 患者自采生殖器外标本虽有可比性能证据,但尚无NAAT获批,使用时需注意说明书范围。
局限性
- 本文为叙述性综述,未报告纳入研究的偏倚评估或异质性分析。
- 未提供各检测具体敏感性、特异性数值及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most commonly reported sexually transmitted infections (STIs) in the United States, and their accurate diagnosis is critical for preventing serious health outcomes. Nucleic acid amplification tests (NAATs) are still considered the gold standard for the laboratory diagnosis of chlamydia and gonorrhea due to their high sensitivity and specificity. Since the 2014 CDC laboratory recommendations, several key improvements to FDA-cleared NAATs have been made including expanded specimen types, technology, and process improvements. METHODS: We conducted a systematic literature search and a narrative review focused on the performance of laboratory-based molecular diagnostics for CT and NG. This systematic review evaluated 145 studies to assess current diagnostic performance, focusing on six key areas: FDA-cleared diagnostic NAATs, self-collected specimens, pooling strategies, time to negativity, confirmatory/repeat testing, and LGV diagnostics. RESULTS: Many assays now include claims for clinician-collected extragenital specimens and self-collected vaginal swabs with high sensitivity (>90%) and specificity (>98%), and the recent FDA authorization of the first self-collection kit for nonclinical settings represents a major milestone in STI care access. However, no NAATs currently have claims for patient-collected extragenital specimens, despite strong evidence of comparable performance and high patient acceptability. Newer versions of assays incorporate dual targets for both CT and NG to enhance positive predictive value and reduce diagnostic escape. While no FDA-cleared assays exist for LGV differentiation, several laboratory-developed tests show promise. CONCLUSIONS: Future directions include expanding FDA clearance for self-collected extragenital specimens and developing viability assays to better distinguish active infection from residual nucleic acids. Together, these advances underscore the progress in CT/NG testing and highlight opportunities to further improve diagnostic reach and clinical relevance.
引用
- Crumpler M, Realegeno SE, Shakir SM, et al. Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae. Clin Infect Dis. 2026. PMID: 41733547. doi:10.1093/cid/ciaf696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。